Jump to content
  • Dossier Advanced therapy medicinal products

    Novel gene and cell therapies are associated with high expectations in the treatment of incurable and hereditary diseases. Among them, CAR-T cell therapies have emerged as a major hope in cancer treatment.
    © BIOPRO Baden-Württemberg GmbH

  • Contact Stay in touch

    Would you like continue receiving e-mail notifications about our activities, up-to-date information, events, opportunities for cooperation and general industry information? Register here to stay informed about current issues.
    © denisismagilov / Adobe Stock

  • Industry report The healthcare industry in Baden-Württemberg

    BIOPRO's new report entitled "Healthcare Industry 2020: Facts and Figures for Baden-Württemberg" illustrates key figures like num the number of companies, number of employees and taxable turnover for the biotechnology, medical technology and pharmaceutical industry.
    © MR.LIGHTMAN / Adobe Stock


Latest news

  • Press release - 23/06/2021

    For the first time, scientists from the German Cancer Consortium (DKTK) partner site in Essen/Düsseldorf have discovered stem cells of the hematopoietic system in glioblastomas, the most aggressive form of brain tumor. These hematopoietic stem cells promote division of the cancer cells and at the same time suppress the immune response against the tumor.

  • Article - 22/06/2021

    Outdated and inadequate methods of neurological rehabilitation are still being used for patients with neurological diseases or injuries – and what’s more, the treatment is usually too late. This is because cognitive training is especially important in the critical phases when the brain is particularly plastic. The Heidelberg-based company living brain proves that early treatment is possible using an extremely innovative method – with concentrated…

  • Press release - 17/06/2021

    Which neurons in the brain mediate fear responses - and how do they flip the switch when the danger is over? The research team of Prof. Ingrid Ehrlich at the Institute of Biomaterials and Biomolecular Systems (IBBS), Department of Neurobiology studies these questions. Their latest results obtained in collaboration with scientists at the Friedrich Miescher Institute in Basel (Switzerland), the National Institute of Health (USA), and Innsbruck…

  • Press release - 16/06/2021

    CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced results of the second interim analysis of its international pivotal Phase 2b/3 study in approximatively 40,000 subjects (the HERALD study) of CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV.

  • Press release - 10/06/2021

    Effective drugs for the treatment of diseases of the central nervous system do exist. However, the blood-brain barrier, which protects the brain as the body's control center, makes it especially difficult for therapeutic biomolecules to pass through. Thus, researchers from an international consortium coordinated by the Fraunhofer IGB have spent the last four and a half years developing a novel system in the EU project "N2B-patch"…

Website address: https://www.gesundheitsindustrie-bw.de/en